Approval for a manufacturing change to up-date the laser console portion of the device system from the currently approved hl1 (heart laser(tm)) to the hl2 (hear laser 2).  The device, as modified, will be marketed under the trade name heart laser 2 (hl2), and is indicated for use in the treatment of patients with stable angina (canadian cardiovascular society class 3 or 4) refractory to medical treatment and secondary to objectively demonstrated coronary artery atherosclerosis and with a region of the myocardium not amenable to direct coronary revascularization.